Skip to content
Biotechnology, Medical Health Aged Care

The Future of Skin Science: InMode and ExoCoBio introduce the most clinically validated exosome technology to New Zealand’s aesthetic market.

InMode Australia 2 mins read

This introduction brings one of the world’s most advanced exosome technologies to New Zealand, with two exclusive events set to take place in:

• Auckland – July 15, 2025 | The Boathouse, Park Hyatt Auckland, from 6:30pm

• Christchurch – July 17, 2025 | Chateau on the Park, DoubleTree by Hilton, from 6:30pm

 

These curated evenings will showcase the powerful synergy between ASCE+ Exosomes and InMode’s Morpheus8 technology, and feature:

• Live treatment demonstrations

• Keynote presentations from leading experts in regenerative science

• Clinical case studies and exclusive launch offers for attending practitioners

 

Key Speakers:

Dr Jean Paul Chung, Aesthetic Physician & Educator (Sydney), will present clinical insights and protocols using ASCE+ in skin rejuvenation.

Mr Byong Seung Cho, CEO & CTO of ExoCoBio, South Korea, will offer a rare insider’s perspective into the research and development behind ASCE+, and its role in reshaping global skin health.

 

Powered by ExoSCRT™, ExoCoBio’s proprietary purification technology, ASCE+ Exosomes are designed to optimise cell-to-cell communication, stimulate repair, and visibly revitalise the skin. Backed by science and trusted globally, ASCE+ is now set to raise the standard for non-invasive skin regeneration in the New Zealand market.

 

Adding to this innovation is the InMode Optimas Max, a powerful multi-platform workstation designed to deliver advanced skin treatments across various modalities -including radiofrequency, IPL, and laser technologies. With applicators such as Morpheus8 Burst, Lumecca Peak, and Forma, Optimas Max offers unparalleled versatility for skin resurfacing, tightening, and pigmentation correction - all in one streamlined device. It enables clinics to offer results-driven treatments with minimal downtime and maximum efficacy.

 

When paired with ASCE+ Exosomes, the Optimas Max system becomes a next-generation aesthetic powerhouse. The synergy between energy-based modalities and regenerative exosome therapy enhances treatment outcomes dramatically - accelerating recovery, improving skin texture, and promoting lasting rejuvenation. This combination delivers a compelling value proposition for clinics and practitioners committed to offering cutting-edge, science-backed solutions for their patients.

 

RSVP – https://event.inmodeau.com/asce_exosomes_nz


About us:

About InMode Australia

InMode is a market leader in energy-based medical technologies, providing cutting-edge, clinically validated solutions across Australia and New Zealand.

 

About ExoCoBio

ExoCoBio is a globally recognised innovator in exosome therapeutics and regenerative aesthetics, dedicated to delivering science-driven skincare solutions through advanced biologics.


Contact details:

Media Contact:
Patricia Amalm
Mobile: 0499 197 069
Email:
[email protected]
Website:
www.inmode.com.au

Follow Us on Instagram

Media

More from this category

  • Medical Health Aged Care
  • 11/08/2026
  • 21:17
Dark Horse Consulting Group

Dark Horse Consulting Group Expands into China, Appoints Kang Liu as Senior Director, Head of China

WALNUT CREEK, Calif. and SHANGHAI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (DHCG), a leading life sciences consulting firm specializing in advanced therapies, today announced the formation of Dark Horse Consulting China and the appointment of Kang Liu, Ph.D. as its inaugural hire. The new office, located in Shanghai, reflects DHCG’s strategic commitment to helping biotherapeutic developers capitalize on China’s rapidly advancing life sciences ecosystem, including its world-class CDMO and CRO infrastructure, streamlined regulatory pathways to first-in-human (FIH), and growing role as a global hub for clinical data generation.The timing of this expansion is deliberate. China’s life…

  • Medical Health Aged Care
  • 11/08/2026
  • 15:19
Galderma

Galderma Receives European Union Approval for Restylane® Shaype(TM): the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin…

  • Contains:
  • Medical Health Aged Care
  • 11/08/2026
  • 15:00
Royal Australian College of GPs

GPs have a pivotal role to play in improving menopause care, highlights AJGP

The Royal Australian College of GPs (RACGP) has released the latest issue of theAustralian Journal of General Practice (AJGP), themed‘Menopause 2’,highlightingthecritical role GPs play in improving menopause care and addressing long-standing gaps in education,diagnosisand treatment. Building on the AprilAJGPissue,‘Menopause1’,this edition explores the assessment and management of commonlyoverlooked menopause-related conditions. Thelatest evidence to support GPs in deliveringpatient-centred careis also spotlighted. RACGP Expert Committee – Quality Care member and women's health spokesperson Associate Professor Magdalena Simonissaid the issue reinforces why menopause is an essential part of general practice and why better awareness amongthe clinician community, including GPs,is needed. “Women deserve access to…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.